Business Context and Reporting Period
Allogene Therapeutics, Inc. filed this Form 8-K under Item 8.01 on June 15, 2023, reporting updated clinical data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A, allogeneic CD19-directed CAR T-cell candidates, in patients with relapsed/refractory large B-cell lymphoma (LBCL). The analysis had an April 20, 2023 data cutoff and covered 33 CAR T-naive patients treated with material manufactured using the Alloy manufacturing process.
Key Clinical and Financial Information
| Metric | Result |
|---|---|
| Patients evaluated | 33 |
| Overall response rate | 19 patients, or 58% |
| Complete response rate | 14 patients, or 42% |
| Complete response at six months | 10 patients, or 30% |
| Phase 2 regimen response rate | 8 of 12 patients, or 67% |
| Phase 2 regimen complete response rate | 7 of 12 patients, or 58% |
| Median duration of response | 23.1 months for both the overall population and Phase 2 regimen group |
| Median enrollment-to-treatment time | Three days |
| Patients receiving product meeting specifications | 100% |
The filing does not provide revenue, profitability, cash flow, margins, debt, liquidity, or other corporate financial metrics. No bridging therapy was used. Lymphodepletion regimens varied, including FCA90, lower-dose ALLO-647 regimens, and split regimens used with consolidation dosing.
Material Changes and Clinical Safety
- Updated results covered all 33 eligible patients, compared with an earlier ASCO presentation covering 12 patients treated with the Phase 2 regimen.
- Complete responses were more frequent in regimens containing 90 mg of ALLO-647, including the FCA90 Phase 2 regimen.
- No Grade 3 or higher cytokine release syndrome was reported.
- No cases of ICANS or graft-versus-host disease were reported.
- Across all patients, neurotoxicity occurred in 13 patients, infections in 19, infusion-related reactions in 16, and prolonged Grade 3 or higher cytopenia in 4. The filing characterizes cytopenias and infections as manageable.
Guidance, Outlook, Risks, and Unusual Items
Allogene stated that it was enrolling the potentially pivotal Phase 2 ALPHA2 trial of ALLO-501A in LBCL and expected to complete enrollment in the first half of 2024. The company also expected to open trial sites in Europe, Canada, and Australia during 2023.
Key risks include the preliminary nature and limited size of the Phase 1 data, potential changes in results with additional follow-up, patient-enrollment challenges, manufacturing and product-optimization issues, adverse events, regulatory disagreement or delays, inability to demonstrate safety or efficacy, intellectual-property matters, COVID-19 impacts, and the need for additional financing. Comparisons with autologous CAR T therapies may not be meaningful because of differences in trial design, patient populations, follow-up, and products.
Facts Investors Should Verify
- Whether the Phase 2 ALPHA2 trial met its enrollment and timing expectations.
- Durability of complete responses and whether the reported 23.1-month median duration is sustained in longer follow-up.
- Whether the Phase 2 regimen’s response rates are replicated in a larger, potentially pivotal study.
- Updated rates and severity of infections, cytopenias, neurotoxicity, and other treatment-related events.
- Manufacturing consistency, regulatory feedback, trial-site expansion, and Allogene’s available financing and cash runway, which are not provided in this filing.